Chang Han Selected Research

ONO-DI-004

4/2006	Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
6/2005	Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chang Han Research Topics

Disease

35	Neoplasms (Cancer) 01/2023 - 08/2002
21	Cholangiocarcinoma 12/2022 - 08/2002
10	Hepatocellular Carcinoma (Hepatoma) 01/2017 - 04/2002
9	Inflammation (Inflammations) 03/2021 - 01/2004
7	Carcinogenesis 01/2019 - 10/2004
5	Lung Neoplasms (Lung Cancer) 01/2023 - 10/2020
5	Liver Neoplasms (Liver Cancer) 01/2017 - 09/2003
4	Infections 01/2023 - 11/2013
4	Liver Diseases (Liver Disease) 01/2022 - 12/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 01/2021
3	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2017
3	Necrosis 01/2017 - 12/2008
2	Fibrosis (Cirrhosis) 01/2022 - 05/2019
2	Atherosclerosis 12/2021 - 04/2002
2	Second Primary Neoplasms (Neoplasms, Second) 10/2021 - 09/2021
2	Glioma (Gliomas) 09/2021 - 04/2016
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021 - 05/2019
2	Non-alcoholic Fatty Liver Disease 01/2020 - 04/2016
2	Hemorrhage 01/2016 - 12/2008
2	Obesity 11/2006 - 04/2002
1	Triple Negative Breast Neoplasms 01/2023
1	Adenocarcinoma of Lung 01/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023
1	Prostatic Neoplasms (Prostate Cancer) 02/2022
1	Human Influenza (Influenza) 01/2022
1	Anemia 01/2022
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Rectal Neoplasms (Rectal Cancer) 01/2022
1	Sepsis (Septicemia) 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Myocardial Infarction 12/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2021
1	Aneurysm (Aneurysms) 12/2021

Drug/Important Bio-Agent (IBA)

12	Dinoprostone (PGE2)FDA Link 01/2017 - 10/2004
11	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 06/2014 - 08/2002
8	ProstaglandinsIBA 09/2009 - 08/2002
7	15-hydroxyprostaglandin dehydrogenaseIBA 03/2022 - 01/2008
6	MicroRNAs (MicroRNA)IBA 12/2022 - 07/2012
6	Proteins (Proteins, Gene)FDA Link 10/2020 - 07/2013
6	EnzymesIBA 04/2015 - 04/2002
6	Prostaglandins EIBA 02/2008 - 08/2002
5	LipidsIBA 04/2015 - 04/2002
4	Alanine Transaminase (SGPT)IBA 01/2020 - 12/2008
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020 - 12/2008
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2015 - 04/2002
4	EicosanoidsIBA 02/2008 - 04/2002
3	RNA (Ribonucleic Acid)IBA 01/2023 - 10/2015
3	Therapeutic UsesIBA 12/2021 - 11/2009
3	Phosphotransferases (Kinase)IBA 10/2020 - 04/2006
3	CytokinesIBA 01/2020 - 01/2004
3	15-ketoprostaglandin E2IBA 01/2017 - 07/2013
3	CaspasesIBA 01/2016 - 09/2009
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 04/2015 - 01/2008
3	PPAR gammaIBA 11/2013 - 07/2003
3	LigandsIBA 07/2013 - 07/2003
3	beta CateninIBA 11/2009 - 01/2008
3	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 12/2008 - 03/2004
3	PPAR deltaIBA 10/2008 - 11/2006
3	Arachidonic Acid (Vitamin F)IBA 02/2008 - 01/2004
3	Group IV Phospholipases A2IBA 02/2008 - 10/2004
3	Phospholipases (Phospholipase)IBA 10/2004 - 04/2002
3	Celecoxib (Celebrex)FDA Link 03/2004 - 09/2003
2	Immune Checkpoint InhibitorsIBA 01/2023 - 09/2021
2	GSK-2816126IBA 12/2022 - 10/2017
2	Long Noncoding RNAIBA 09/2021 - 01/2019
2	Carcinoembryonic AntigenIBA 01/2020 - 01/2020
2	tyrosine receptor (receptor, tyrosine)IBA 01/2017 - 04/2006
2	EndotoxinsIBA 01/2017 - 12/2008
2	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 12/2015
2	Messenger RNA (mRNA)IBA 10/2015 - 05/2013
2	ErbB Receptors (EGF Receptor)IBA 07/2015 - 06/2005
2	3' Untranslated Regions (3' UTR)IBA 10/2014 - 05/2013
2	TensinsIBA 10/2014 - 06/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2014 - 06/2011
2	Transaminases (Aminotransferases)IBA 12/2011 - 09/2009
2	Docosahexaenoic AcidsIBA 11/2011 - 01/2008
2	Epidermal Growth Factor (EGF)IBA 06/2011 - 06/2005
2	Transforming Growth Factor beta (TGF-beta)IBA 08/2010 - 10/2004
2	DNA (Deoxyribonucleic Acid)IBA 08/2008 - 08/2006
2	Interleukin-6 (Interleukin 6)IBA 08/2006 - 08/2002
2	ONO-DI-004IBA 04/2006 - 06/2005
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2004 - 08/2002
1	ProteomeIBA 01/2023
1	Blood Proteins (Serum Proteins)IBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	Calcium-Calmodulin-Dependent Protein Kinase KinaseIBA 01/2023
1	Histones (Histone)IBA 12/2022
1	Lysine (L-Lysine)FDA Link 12/2022
1	Histone MethyltransferasesIBA 03/2022

Therapy/Procedure

9	Therapeutics 12/2021 - 02/2008
4	Immunotherapy 01/2023 - 09/2021
4	Radiotherapy 02/2022 - 10/2020
4	Drug Therapy (Chemotherapy) 09/2021 - 10/2020
3	Chemoprevention 11/2009 - 11/2006
2	Lymph Node Excision (Lymph Node Dissection) 01/2020 - 01/2020
1	Length of Stay 01/2022
1	Neoadjuvant Therapy 01/2022